The purpose of the Administration Core is to support the translational research objectives of our SPORE in Thyroid Cancer by serving as the organizational hub, optimizing collaboration annong SPORE investigators within and outside MSKCC.
The specific aims ofthe Administrative Core are 1) Provide coordination for all educational and scientific activities ofthe SPORE and 2) Provide centralized administrative support of day- to-day activities to all the components of the SPORE: research projects, cores, and developmental programs. The core will perform the following centralized duties: ? Scientific Review Coordination: Organize the scientific review of ongoing SPORE research projects, cores, and pilot projects as well as the annual solicitation of new pilot projects ? Collaboration: Foster collaborative research within our SPORE as well as with other SPOREs and the wider scientific community ? Financial Management: Serve as the centralized SPORE budgetary coordinator and financial manager ? Editorial Services: Provide editorial services for manuscript publication and grants coordination ? Grants Administration: Serve as administrative liaison to the National Cancer Institute, ensuring the timely submission of all required reports and compliance with institutional and federal regulations. The Administrative Core is led by James Fagin, MD, the SPORE Project Director/Principal Investigator, who will oversee all SPORE activities. Steven Larson, MD will serve as the Co-Director on the core and assist Dr. Fagin. The Administrative Core also includes Jeffrey Knauf, PhD, who will coordinate collaborations, educational functions and meetings, and Mr Matthew Skernolis, who will serve as the financial manager, administrator ofthe grant and coordinate communications with the National Cancer Institute and compliance with institutional and federal regulations.
The Administrative Core serves the essential purpose of centralizing and optimizing collaboration between SPORE investigators. In addition it will provide the institutional environment for proper monitoring of scientific progress, administrative compliance and financial management.
|Mio, Catia; Lavarone, Elisa; Conzatti, Ketty et al. (2016) MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocr Relat Cancer 23:335-47|
|Landa, IÃ±igo; Ibrahimpasic, Tihana; Boucai, Laura et al. (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052-66|
|Mandal, Rajarsi; Chan, Timothy A (2016) Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discov 6:703-13|
|Champa, Devora; Orlacchio, Arturo; Patel, Bindi et al. (2016) Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis. Oncotarget 7:34453-71|
|Brito, Juan P; Ito, Yasuhiro; Miyauchi, Akira et al. (2016) A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. Thyroid 26:144-9|
|Brown, Anna M; Nagala, Sidhartha; McLean, Mary A et al. (2016) Multi-institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. Magn Reson Med 75:1708-16|
|Vedvyas, Yogindra; Shevlin, Enda; Zaman, Marjan et al. (2016) Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight 1:e90064|
|Garcia-Rendueles, Maria E R; Ricarte-Filho, Julio C; Untch, Brian R et al. (2015) NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discov 5:1178-93|
|Dunn, Lara; Fagin, James A (2015) Therapy: Lenvatinib and radioiodine-refractory thyroid cancers. Nat Rev Endocrinol 11:325-7|
|Wiesner, Thomas; Lee, William; Obenauf, Anna C et al. (2015) Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature 526:453-7|
Showing the most recent 10 out of 14 publications